Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in SD rats

Parkinson's Disease

Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469 · see citing works

Biodegradation and biocompatibility of PLA and PLGA microspheres

Anderson, J. M., & Shive, M. S. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00048-3 · Cited by 2,617 · see citing works

Polymer microspheres for controlled drug release

Freiberg, S., & Zhu, X. X. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.04.013 · Cited by 1,339 · see citing works

Dopamine as a Prolactin (PRL) Inhibitor

Ben-Jonathan, N., & Hnasko, R. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.6.0451 · Cited by 983 · see citing works

Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications

Olanow, C. W., Obeso, J. A., & Stocchi, F. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70521-x · Cited by 549 · see citing works

Is dopamine a physiologically relevant mediator of feeding behavior?

Palmiter, R. D. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.06.004 · Cited by 469 · see citing works

Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap

Calabresi, P., Filippo, M. D., Ghiglieri, V., Tambasco, N., & Picconi, B. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70218-0 · Cited by 390 · see citing works

Muscular exercise can cause highly pathological liver function tests in healthy men

Pettersson, J., Hindorf, U., Persson, P., Bengtsson, T., Malmqvist, U. P., Werkström, V., & Ekelund, M. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.03001.x · Cited by 357 · see citing works

Parkinson's disease in a Scottish city.

Mutch, W. J., Dingwall-Fordyce, I., Downie, A. W., Paterson, J. G., & Roy, S. K. (1986) · BMJ · doi:10.1136/bmj.292.6519.534 · Cited by 255 · see citing works

Feeding behavior in dopamine-deficient mice

Szczypka, M. S., Rainey, M. A., Kim, D. S., Alaynick, W. A., Marck, B. T., Matsumoto, A. M., & Palmiter, R. D. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.21.12138 · Cited by 242 · see citing works

Milestones in Parkinson's disease therapeutics

Rascol, O., Lozano, A. M., Stern, M., & Poewe, W. H. (2011) · Movement Disorders · doi:10.1002/mds.23714 · Cited by 195 · see citing works

Resting and post‐exercise serum biomarkers of cardiac and skeletal muscle damage in adolescent runners

Nie, J., Tong, T. K., George, K., Fu, F. H. K., Lin, H., & Shi, Q. (2010) · Scandinavian Journal of Medicine and Science in Sports · doi:10.1111/j.1600-0838.2010.01096.x · Cited by 113 · see citing works

Dopamine in gastrointestinal disease

Glavin, G. B., & Szabó, S. (1990) · Digestive Diseases and Sciences · doi:10.1007/bf01537589 · Cited by 110 · see citing works

Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women

Kok, P., Roelfsema, F., Frölich, M., PELT, J. V., Stokkel, M. P. M., Meinders, A. E., & Pijl, H. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00567.2005 · Cited by 107 · see citing works

Dopamine D2 receptor knock-out mice are insensitive to the hypolocomotor and hypothermic effects of dopamine D2/D3 receptor agonists

Boulay, D., Depoortère, R., Perrault, G., Borrelli, E., & Sanger, D. J. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00064-7 · Cited by 106 · see citing works

Therapies for dopaminergic‐induced dyskinesias in parkinson disease

Gottwald, M. D., & Aminoff, M. J. (2011) · Annals of Neurology · doi:10.1002/ana.22423 · Cited by 100 · see citing works

Dopamine Receptor Subtype Agonists and Feeding Behavior

Terry, P., Gilbert, D. B., & Cooper, S. J. (1995) · Obesity Research · doi:10.1002/j.1550-8528.1995.tb00221.x · Cited by 74 · see citing works

Transdermal Rotigotine: A Clinically Innovative Dopamine‐Receptor Agonist for the Management of Parkinson's Disease

Chen, J. J., Swope, D., Dashtipour, K., & Lyons, K. E. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.12.1452 · Cited by 73 · see citing works

Protective Effects of L-Arginine Supplementation against Exhaustive Exercise-Induced Oxidative Stress in Young Rat Tissues

Huang, C. (2009) · The Chinese Journal of Physiology · doi:10.4077/cjp.2009.amh068 · Cited by 70 · see citing works

Rotigotine Transdermal Patch

Sanford, M., & Scott, L. J. (2011) · CNS Drugs · doi:10.2165/11206750-000000000-00000 · Cited by 63 · see citing works

Co-administration of dopamine D1 and D2 agonists additively decreases daily food intake, body weight and hypothalamic neuropeptide Y level in rats

Kuo, D. (2002) · Journal of Biomedical Science · doi:10.1007/bf02256023 · Cited by 62 · see citing works

New pharmacological avenues for the treatment of l -DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors

Blandini, F., & Armentero, M. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.651457 · Cited by 61 · see citing works

Investigation of the degradation behaviour of poly(ethylene glycol-co-d,l-lactide) copolymer

Dorati, R., Genta, I., Colonna, C., Modena, T., Pavanetto, F., Perugini, P., & Conti, B. (2007) · Polymer Degradation and Stability · doi:10.1016/j.polymdegradstab.2007.06.020 · Cited by 50 · see citing works

Duodenal levodopa infusion for the treatment of Parkinson’s disease

Samanta, J., & Hauser, R. A. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.5.657 · Cited by 48 · see citing works

Dopamine interrupts gastrointestinal fed motility pattern in humans

Marzio, L., Neri, M., Pieramico, O., Donne, M. D., Peeters, T. L., & Cuccurullo, F. (1990) · Digestive Diseases and Sciences · doi:10.1007/bf01537410 · Cited by 43 · see citing works

Preparation of Rotigotine-Loaded Microspheres and Their Combination Use with L-DOPA to Modify Dyskinesias in 6-OHDA-Lesioned Rats

Wang, A., Wang, L., Sun, K., Liu, W., Sha, C., & Li, Y. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0762-0 · Cited by 42 · see citing works

The enantiomers of the D-2 dopamine receptor agonist N-0437 discriminate between pre- and postsynaptic dopamine receptors

van der Weide, J., Tendijck, M. E. C., Tepper, P. G., Vries, J. B. D., Dubocovich, M. L., & Horn, A. S. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90309-3 · Cited by 40 · see citing works

Rotigotine Transdermal Patch

Baldwin, C. M., & Keating, G. M. (2007) · CNS Drugs · doi:10.2165/00023210-200721120-00007 · Cited by 40 · see citing works

Characterization of Dopamine Receptor Subtypes Involved in Experimentally Induced Gastric and Duodenal Ulcers in Rats

Desai, J. K., Goyal, R. K., & Parmar, N. S. (1999) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357991772123 · Cited by 40 · see citing works

Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements

Schmidt, W., Lebsanft, H. B., Heindl, M., Gerlach, M., Grünblatt, E., Riederer, P. F., Mayerhofer, A., & Scheller, D. K. A. (2008) · Journal of Neural Transmission · doi:10.1007/s00702-008-0102-z · Cited by 33 · see citing works

Co-Administration of Dopamine D1 and D2 Agonists Additively Decreases Daily Food Intake, Body Weight and Hypothalamic Neuropeptide Y Level in Rats

Kuo, D. (2002) · Journal of Biomedical Science · doi:10.1159/000048208 · Cited by 32 · see citing works

Continuous dopaminergic stimulation and novel formulations of dopamine agonists

Stocchi, F. (2011) · Journal of Neurology · doi:10.1007/s00415-011-6024-y · Cited by 30 · see citing works

Continuous rotigotine administration reduces dyskinesia resulting from pulsatile treatment with rotigotine or l-DOPA in MPTP-treated common marmosets

Stockwell, K., Scheller, D., Smith, L. A., Rose, S., Iravani, M. M., Jackson, M. J., & Jenner, P. G. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.10.004 · Cited by 29 · see citing works

Central dopamine involvement in experimental gastrointestinal injury

Glavin, G. B. (1992) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(92)90073-n · Cited by 27 · see citing works

Transdermal delivery of dopamine receptor agonists

Reichmann, H. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70843-0 · Cited by 25 · see citing works

Review: Therapeutic options for continuous dopaminergic stimulation in Parkinson's disease

Sujith, O. K., & Lane, C. J. (2009) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285608101378 · Cited by 23 · see citing works

Continuous dopaminergic stimulation achieved by duodenal levodopa infusion

Odin, P., Wolters, E. C., & Antonini, A. (2008) · Neurological Sciences · doi:10.1007/s10072-008-1054-7 · Cited by 22 · see citing works

Drug safety evaluation of rotigotine

Sprenger, F., Seppi, K., & Poewe, W. H. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.678830 · Cited by 20 · see citing works

Continuous dopaminergic delivery in Parkinson’s disease

Antonini, A., Ursino, G., Calandrella, D., Bernardi, L., & Plebani, M. (2010) · Journal of Neurology · doi:10.1007/s00415-010-5714-1 · Cited by 19 · see citing works

Plasma levels of rotigotine and the reversal of motor deficits in MPTP-treated primates

Rose, S., Scheller, D. K. A., Breidenbach, A., Smith, L. A., Jackson, M., Stockwell, K., & Jenner, P. G. (2007) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3280ebb400 · Cited by 18 · see citing works

Effects of bromocriptine on serum prolactin levels, pituitary weight and immunoreactive prolactin cells in estradiol-treated ovariectomized rats: an experimental model of estrogen-dependent hyperprolactinemia

Ribeiro, M. F. M., Spritzer, P. M., Barbosa-Coutinho, L. M., Oliveira, M. C., Pavanato, M. A., Silva, I. S. B., & dos Reis, F. M. (1997) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x1997000100017 · Cited by 12 · see citing works

Role of dopamine receptors in gastrointestinal motility.

Dhasmana, K. M., Banerjee, A. K., Zhu, Y. N., Erdmann, W., Parmar, S. S., & Salzman, S. K. (1989) · PubMed · Cited by 10 · see citing works

The role of endogenous gonadotropin release in the etiology of ovarian enlargement during purified urinary follicle-stimulating hormone therapy

Mizunuma, H., Takagi, T., 山田, 清., Andoh, K., Ibuki, Y., & Igarashi, M. (1991) · Fertility and Sterility · doi:10.1016/s0015-0282(16)54061-8 · Cited by 6 · see citing works

Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles

Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645 · see citing works

Drug Delivery Systems for Imaging and Therapy of Parkinson';s Disease

Silindir‐Gunay, M., Özer, A. Y., & Chalon, S. (2015) · Current Neuropharmacology · doi:10.2174/1570159x14666151230124904 · Cited by 81 · see citing works

Advances in Nanomedicine for the Treatment of Alzheimer’s and Parkinson’s Diseases

Hernando, S., Gartziandia, O., Herrán, E., Pedraz, J. L., Igartúa, M., & Hernández, R. M. (2016) · Nanomedicine · doi:10.2217/nnm-2016-0019 · Cited by 48 · see citing works

Lipopolysaccharide/D-galactosamine-induced acute liver injury could be attenuated by dopamine receptor agonist rotigotine via regulating NF-κB signaling pathway

Yue, S., Wang, T., Yang, Y., Fan, Y., Zhou, L., Li, M., & Fu, F. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107798 · Cited by 27 · see citing works

Environmentally Oriented Models and Methods for the Evaluation of Drug × Drug Interaction Effects

Wieczerzak, M., Kudłak, B., & Namieśnik, J. (2014) · Critical Reviews in Analytical Chemistry · doi:10.1080/10408347.2014.899467 · Cited by 15 · see citing works

Nanodelivery of therapeutic agents in Parkinson's disease

Lafuente, J. V., Requejo, C., & Ugedo, L. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.03.004 · Cited by 14 · see citing works

Virtual structure-based docking and molecular dynamics of FDA-approved drugs for the identification of potential IKKB inhibitors possessing dopaminergic activity in Alzheimer’s disease

Gurram, P. C., Satarker, S., Nassar, A., Mudgal, J., & Nampoothiri, M. (2022) · Chemical Papers · doi:10.1007/s11696-022-02598-y · Cited by 12 · see citing works

Unraveling the Ties: Type 2 Diabetes and Parkinson's Disease - A Nano-Based Targeted Drug Delivery Approach

De, S., Banerjee, S., Rakshit, P., Banerjee, S., & Kumar, S. K. A. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998291968240429111357 · Cited by 6 · see citing works

Nanocarriers to mediate the pathways from diabetes toward Parkinson's disease

De, S., & Kuo, Y. (2024) · Journal of the Taiwan Institute of Chemical Engineers · doi:10.1016/j.jtice.2024.105401 · Cited by 5 · see citing works

A study of the genotoxicity, fertility and early embryonic development toxicity of rotigotine behenate extended‐release microspheres

Zhao, X., Guo, C., Zhang, H., Yu, X., Du, G., Tian, J., Liu, W., Song, T., Chen, X., & Guo, W. (2023) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13972 · Cited by 4 · see citing works

20-Week toxicity study of rotigotine behenate extended-release microspheres for intramuscular injection in sprague dawley rats

Lv, W., Zhang, H., Chen, Y., Wu, M., Qin, C., Yin, Z., Zhao, X., Guo, W. Y., Cen, X., Yu, X., et al. (2025) · Food and Chemical Toxicology · doi:10.1016/j.fct.2025.115384 · Cited by 2 · see citing works

Preclinical Evaluation of the Oral Toxicity, Genotoxicity, and Safety Pharmacology of LPM4870108 , a Novel Potent Tropomyosin Receptor Kinase Inhibitor

Zhang, X., Yuan, B., Li, C., Wang, H., Wei, S., Tian, J., & Duan, S. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70153 · Cited by 1 · see citing works

Basics of Targeted Drug Delivery

Doshi, K. A. (2022) · Methods and principles in medicinal chemistry · doi:10.1002/9783527827855.ch1 · Cited by 1 · see citing works

Pharmacodynamics, safety pharmacology and local tolerance of rotigotine behenate extended-release microspheres

Chen, Y., Yin, Z., Qin, C., Wu, M., Lv, W., Zhao, X., Xiaoyin, Z., Du, G., Tian, J., Yu, X., et al. (2025) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2025.117478

Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in Cynomolgus monkeys

Tian, J., Du, G., Ye, L., Yu, X., Zhang, J., Wang, H., Yu, P., Fu, F., Liu, W., Li, Y., et al. (2013) · Food and Chemical Toxicology · doi:10.1016/j.fct.2012.11.010 · Cited by 15 · see citing works

20-Week intramuscular toxicity study of rotigotine behenate extended-release microspheres for injection via intramuscular injection in cynomolgus monkeys

Zhao, X., Guo, C., Zhang, H., Yu, X., Zhu, X., Du, G., Tian, J., Liu, W., Song, T., Chen, X., et al. (2024) · Food and Chemical Toxicology · doi:10.1016/j.fct.2024.114786 · Cited by 4 · see citing works

20-Week toxicity study of rotigotine behenate extended-release microspheres for intramuscular injection in sprague dawley rats

Lv, W., Zhang, H., Chen, Y., Wu, M., Qin, C., Yin, Z., Zhao, X., Guo, W. Y., Cen, X., Yu, X., et al. (2025) · Food and Chemical Toxicology · doi:10.1016/j.fct.2025.115384 · Cited by 2 · see citing works

Preparation of Rotigotine-Loaded Microspheres and Their Combination Use with L-DOPA to Modify Dyskinesias in 6-OHDA-Lesioned Rats

Wang, A., Wang, L., Sun, K., Liu, W., Sha, C., & Li, Y. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0762-0 · Cited by 42 · see citing works

Pharmacodynamics, safety pharmacology and local tolerance of rotigotine behenate extended-release microspheres

Chen, Y., Yin, Z., Qin, C., Wu, M., Lv, W., Zhao, X., Xiaoyin, Z., Du, G., Tian, J., Yu, X., et al. (2025) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2025.117478